Glen Joel Weiss MD

Oncology•Boston, MA

Physician

Join to View Full Profile

665 Washington St Unit 1015Boston, MA 02111
Phone+1 928-487-5282
Fax+1 623-321-1528

Education & Training

University of ColoradoFellowship, Hematology and Medical Oncology, 2004 - 2007
University of Colorado School of MedicineFellowship, Hematology and Medical Oncology, 2007
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 2001 - 2004
SUNY Downstate Health Sciences UniversityInternship, Internal Medicine, 2001 - 2002
Tel Aviv University SacklerClass of 2001
OtherClass of 2001

Certifications & Licensure

MA State Medical License 2018 - 2026
AZ State Medical License 2007 - 2020
CO State Medical License 2004 - 2007
National Board of Physicians and Surgeons Internal Medicine
National Board of Physicians and Surgeons Medical Oncology
Medical Oncology, Internal Medicine

Clinical Trials

A Study of Intravenous XMT-1001 in Patients With Advanced Solid Tumors Start of enrollment: 2011 Mar 01
Completed
Phase 1
Saliva mRNA Expression Profiling for Early Stage Non-Small Cell Lung Cancer Screening Start of enrollment: 2007 Aug 01
Terminated
Phase II Study Of Oral PHA-848125AC In Patients With Thymic Carcinoma Start of enrollment: 2010 Feb 22
Terminated
Phase 2
Study of NMS-1286937 in Adult Patients With Advanced/Metastatic Solid Tumors Start of enrollment: 2009 Nov 01
Completed
Phase 1
An Ancillary Pilot Trial Using Whole Genome Sequencing In Patients With Advance Refractory Cancer Start of enrollment: 2011 Sep 01
Completed
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113) Start of enrollment: 2011 Sep 20
Completed
Phase 1, Phase 2
Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer Start of enrollment: 2013 Apr 01
Terminated
Phase 2
Study of Immunochemotherapy +/- Hypofractionated Radiation for Complete Response in Solid Tumors Start of enrollment: 2013 Jun 01
Withdrawn
Not Applicable
Study of Carfilzomib With Irinotecan in Irinotecan-Sensitive Malignancies and Small Cell Lung Cancer Patients Start of enrollment: 2013 Nov 01
Completed
Phase 1, Phase 2
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
A Safety Trial of Nivolumab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed During or After Receiving At Least One Prior Chemotherapy Regimen Start of enrollment: 2014 Apr 09
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

8 citations
Review of the use of radiomics to assess the risk of recurrence in early-stage non-small cell lung cancer.
William Adam Libling, Ronald Korn, Glen J Weiss
Translational Lung Cancer Research. 2023-07-31
17 citations
Non-small cell lung cancer patients treated with Anti-PD1 immunotherapy show distinct microbial signatures and metabolic pathways according to progression-free surviva...
David Dora, Balazs Ligeti, Tamas Kovacs, Peter Revisnyei, Gabriella Galffy
Oncoimmunology. 2023-01-01
4 citations
Glypican-3 (GPC3) is associated with MCPyV-negative status and impaired outcome in Merkel cell carcinoma.
Sujatha Muralidharan, Thibault Kervarrec, Glen J Weiss, Mahtab Samimi
Oncotarget. 2022-01-01

Press Mentions

Oncotarget | Glypican-3 (GPC3) Is Associated with MCPyV-Negative Status and Impaired Outcome in Merkel Cell CarcinomaAugust 11th, 2022
CIRCULOGENE’s Precision Genomic Profiling Technology Featured in Three AACR 2019 AbstractsMarch 25th, 2019
CIRCULOGENE Appoints Dr. Glen J. Weiss as Chief Medical OfficerNovember 28th, 2017
Join now to see all